Division of Basic & Translational Research, Saroj Gupta Cancer Centre & Research Institute, MG Road, Kolkata 700063, West Bengal, India.
Department of Cancer Immunology, SwasthyaNiketan Integrated Healthcare & Research Foundation, Koramangala, Bengaluru 560034, Karnataka, India.
Cells. 2024 Jul 19;13(14):1221. doi: 10.3390/cells13141221.
The KRAS mutation stands out as one of the most influential oncogenic mutations, which directly regulates the hallmark features of cancer and interacts with other cancer-causing driver mutations. However, there remains a lack of precise information on their cooccurrence with mutated variants of KRAS and any correlations between KRAS and other driver mutations. To enquire about this issue, we delved into cBioPortal, TCGA, UALCAN, and Uniport studies. We aimed to unravel the complexity of and its relationships with other driver mutations. We noticed that G12D and G12V are the prevalent mutated variants of KRAS and coexist with the TP53 mutation in PAAD and CRAD, while G12C and G12V coexist with LUAD. We also noticed similar observations in the case of PIK3CA and APC mutations in CRAD. At the transcript level, a positive correlation exists between and and between and in CRAD. The existence of the co-mutation of KRAS and other driver mutations could influence the signaling pathway in the neoplastic transformation. Moreover, it has immense prognostic and predictive implications, which could help in better therapeutic management to treat cancer.
KRAS 突变是最具影响力的致癌突变之一，它直接调节癌症的标志性特征，并与其他致癌驱动突变相互作用。然而，关于 KRAS 与突变变异体的共同出现以及 KRAS 与其他驱动突变之间的任何相关性，仍然缺乏精确的信息。为了探究这个问题，我们深入研究了 cBioPortal、TCGA、UALCAN 和 Uniport 研究。我们旨在揭示其复杂性及其与其他驱动突变的关系。我们注意到，G12D 和 G12V 是 KRAS 的常见突变变异体，与 PAAD 和 CRAD 中的 TP53 突变共存，而 G12C 和 G12V 与 LUAD 共存。我们还注意到 CRAD 中 PIK3CA 和 APC 突变的类似观察结果。在转录水平上，CRAD 中 与 之间以及 与 之间存在正相关关系。KRAS 与其他驱动突变的共突变可能会影响肿瘤转化中的信号通路。此外，它具有巨大的预后和预测意义，可以帮助更好地进行治疗管理以治疗癌症。
